HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 72.3%

Neg 0% Neu 72.3% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy rating and announces Price Target of $12.